OrbiMed
OrbiMed raises $4.3b for global, Asia funds
Healthcare investor OrbiMed has raised USD 4.3bn for its latest set of global funds, including its fifth Asia-focused vehicle.
Qiming, Orbimed lead Series A for China's Epigenic
Qiming Venture Partners and OrbiMed Asia Partners have led a USD 32m Series A round for Chinese gene editing therapy start-up Epigenic Therapeutics.
Carlyle-backed Adicon trades up after $52m Hong Kong IPO
Adicon Holdings, a China-based independent clinical laboratory (ICL) services provider backed by The Carlyle Group, gained 12% on debut following a HKD 408.9m (USD 52.2m) Hong Kong IPO.
China GPs re-up in ArriVent Biopharma's $155m Series B
Assorted Chinese investors have participated in a USD 155m Series B round for US-headquartered ArriVent Biopharma, which targets drug candidates emanating from emerging biotech hubs, including China.
Hillhouse-backed China pet services business seeks US listing
New Ruipeng Pet Group, a China-based pet care services platform that counts Hillhouse Capital as a significant shareholder, has filed for an IPO in the US.
TPG-backed Dingdang Health raises $51m in Hong Kong IPO
Chinese online pharmacy platform Dingdang Health has raised HKD 402.4m (USD 51m) through a Hong Kong IPO, defying challenging conditions for financial sponsors targeting the bourse.
ABC Impact backs China autism therapy business
ABC Impact, a Singapore-based impact investor established by Temasek Trust, the philanthropic arm of Temasek Holdings, has led a USD 42m Series D for Da Mi & Xiao Mi (DMXM), a Chinese rehabilitation platform for children with autism spectrum disorder...
PE-backed Abbisko trades up after $225m Hong Kong IPO
China-based oncology drug developer Abbisko Therapeutics gained nearly 10% on its Hong Kong trading debut following a HK$1.75 billion ($225 million) IPO.
China's Miaoshou Doctor raises $231m Series F
Beijing Yuanxin Technology, operator of China-based online healthcare services platform Miaoshou Doctor, has raised RMB1.5 billion ($231 million) in Series F funding featuring Sequoia Capital China.
Hong Kong sees rush of VC-backed biotech IPO filings
Five VC-backed pre-revenue Chinese biotech companies have filed to list in Hong Kong over the past two weeks, doubling the size of the IPO pipeline in this category.
PE-backed China dental player files for Hong Kong IPO
Arrail Group, a leading Chinese dental chain that has raised about $400 million in private funding since 2010, has filed for a Hong Kong IPO.
China online pharmacy Dingdang seeks Hong Kong IPO
Dingdang Health, a Chinese online pharmacy business that raised $220 million in funding earlier this month, has filed for a Hong Kong IPO.
TPG leads $220m round for China's Dingdang Health
TPG Capital has led a $220 million round for Chinese online pharmacy services provider Dingdang Health.
China mRNA specialist Stemirna gets $200m in funding
Stemirna Therapeutics, which claims to be the first biotech company to bring an mRNA therapeutics and nanomedicine platform to China, has raised $200 million in funding.
Chinese COVID-19 vaccine developer Clover files for IPO
Clover Biopharmaceuticals, a Chinese pre-revenue drug developer that has raised $315 million across several funding rounds since 2011, has filed for a Hong Kong IPO.
Temasek leads $200m Series E for China's Arrail Dental
Arrail Group, one of China’s largest dental services providers, has raised close to $200 million in Series E funding led by Temasek Holdings.
OrbiMed raises $800m for Asia life sciences fund
OrbiMed has closed its latest Asia life sciences fund, which primarily invests in China and India, with $800 million in commitments.
China’s Clover Biopharmaceuticals gets $230m Series C
Chengdu-based Clover Biopharmaceuticals has raised $230 million in Series C funding led by GL Ventures and Temasek Holdings. Oceanpine Capital, OrbiMed, and Delos Capital all re-upped.
China's AnchorDx completes $40m Series C
AnchorDx, a China-based medical technology developer focused on DNA sequencing and diagnostics, has raised a $40 million Series C round led by OrbiMed and WuXi Huiying Investment.
Sequoia, Tencent lead Series E for China’s Miaoshou Doctor
Beijing Yuanxin Technology, operator of China-based online healthcare services platform Miaoshou Doctor, has raised RMB3 billion ($466 million) in Series E funding led by Sequoia Capital China and Tencent Holdings.
Sequoia leads $150m Series B for China's Visen Pharma
China’s Visen Pharmaceuticals, a drug developer targeting glandular conditions such as dwarfism and growth deficiency has raised a $150 million Series B round led by Sequoia Capital China.
Carlyle leads $123m Series D for China's Abbisko
The Carlyle Group - investing through its Asia growth fund - has led a $123 million Series D round for Chinese cancer-focused biotech developer Abbisko Therapeutics.
PE-backed Harbour BioMed raises $221m in Hong Kong IPO
Harbour BioMed, a Chinese drug developer backed by the likes of Advantech Capital, Legend Capital and GIC, raised HK$1.71 billion ($221 million) through a Hong Kong IPO.
Cell analysis player Cytek raises $120m Series D
RA Capital and Hillhouse Capital have led a $120 million Series D round for Cytek Biosciences, a California-based cell analysis start-up founded by a former professor at Shanghai's Fudan University.